LON:GDR genedrive (GDR) Share Price, News & Analysis GBX 1.34 +0.00 (+0.07%) As of 06:32 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About genedrive Stock (LON:GDR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get genedrive alerts:Sign Up Key Stats Today's Range 1.34▼ 1.3550-Day Range 1.32▼ 1.9052-Week Range 1.30▼ 5.50Volume1.73 million shsAverage Volume4.08 million shsMarket Capitalization£7.61 millionP/E RatioN/ADividend Yield1.57%Price TargetN/AConsensus RatingN/A Company Overviewggenedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.Read More… Receive GDR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for genedrive and its competitors with MarketBeat's FREE daily newsletter. Email Address GDR Stock News HeadlinesGenedrive Secures Additional Funding for Genomic Testing AdvancementsApril 2, 2025 | msn.comGenedrive Share Chat (GDR)September 17, 2024 | lse.co.ukTrump’s Bitcoin Reserve is No Accident…For the first time in history, we have a president who understands crypto's potential to bypass the banking system entirely. And Wall Street's biggest players know it. I've created a blueprint revealing how everyday investors can turn this historic shift into potentially life-changing wealth. Like the 75,000 new millionaires created in the last bull run— only this time with institutional backing.May 28, 2025 | Crypto 101 Media (Ad)ANGLE plc (DWV.F)September 15, 2024 | finance.yahoo.comTRADING UPDATES: FBD pretax profit falls; Getech's retail offerAugust 9, 2024 | lse.co.ukTurkiye Gdr Rgs Share ChatAugust 1, 2024 | lse.co.ukAIM WINNERS & LOSERS: Genedrive gets UK CYP2C19-ID test boostJuly 31, 2024 | lse.co.ukGenedrive PLC: A 2024 Analysis and Future OutlookJuly 19, 2024 | msn.comSee More Headlines GDR Stock Analysis - Frequently Asked Questions How have GDR shares performed this year? genedrive's stock was trading at GBX 2.45 at the start of the year. Since then, GDR shares have decreased by 45.0% and is now trading at GBX 1.35. View the best growth stocks for 2025 here. How were genedrive's earnings last quarter? genedrive plc (LON:GDR) announced its quarterly earnings results on Thursday, March, 27th. The company reported ($0.40) earnings per share (EPS) for the quarter. genedrive had a negative net margin of 1,412.18% and a negative trailing twelve-month return on equity of 191.22%. How do I buy shares of genedrive? Shares of GDR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of genedrive own? Based on aggregate information from My MarketBeat watchlists, some other companies that genedrive investors own include Rolls-Royce Holdings plc (RR.L), B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), Greencore Group (GNC), IQE (IQE) and Omega Diagnostics Group (ODX). Company Calendar Last Earnings3/27/2025Today5/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:GDR Previous SymbolLON:EHP CIKN/A Webwww.genedriveplc.com Phone+44-161-9890245FaxN/AEmployees43Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (3.57) Trailing P/E RatioN/A Forward P/E Ratio0.01 P/E GrowthN/ANet Income-£21.22 million Net Margins-1,412.18% Pretax MarginN/A Return on Equity-191.22% Return on Assets-74.09% Debt Debt-to-Equity Ratio0.35 Current Ratio4.60 Quick Ratio5.52 Sales & Book Value Annual Sales£1.50 million Price / Sales5.06 Cash FlowGBX 0.67 per share Price / Cash Flow2.00 Book ValueGBX 2.83 per share Price / Book0.47Miscellaneous Outstanding Shares567,853,900Free FloatN/AMarket Cap£7.61 million OptionableNot Optionable Beta-0.04 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:GDR) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding genedrive plc Please log in to your account or sign up in order to add this asset to your watchlist. Share genedrive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.